Centaurus (OTC – CTDT) is set to commercialize a disruptive diamond production technology that could transform a $17 billion industry.

Minerco has created a unique, new cross-category beverage category that combines the most popular beverage segments in the non-alcoholic beverage market, and could serve as an alternative to sodas. Hence, a $30M valuation is in the cards.

Today I’d like to introduce you to what I believe is the ideal microcap stock. The name of the company is KSIX Media Holdings, Inc. (OTC – KSIX) and as incredible as it sounds, this company has all of the characteristics investment pros look for in microcaps.

With essentially no direct competition in this treatment category, the addressable market is huge and the impact of an approval for pancreatic cancer sufferers and PharmaCyte shareholders would be enormous.

Multimedia Platforms is the only publicly-traded pure play multimedia company targeting the LGBT demographic. The Company’s potential target market includes 400 million individuals worldwide that identify as lesbian, gay, bisexual, or transgender represents an estimated $3 trillion in buying power.

If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.

With the interest rate concerns behind us, it is time to profile a stock that has such profoundly strong milestones in ahead in 2016 that we believe it will jump from $1 to $5.

Today we are introducing a new idea---a ground floor opportunity, really. One of the fastest growing industries is the mobile gaming market and Pocket Games, Inc. (OTC – PKGM) has a targeted acquisition strategy and very clever approach which has already begun to bear fruit.

PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.

The market may be flirting with year highs but this incredibly undervalued stock has not yet made its move, which we think could occur before year-end. Here’s why, as outlined in a new sponsored research update: